JCR Pharmaceuticals Co., Ltd. (TYO:4552)
473.00
+6.00 (1.28%)
Apr 25, 2025, 3:30 PM JST
JCR Pharmaceuticals Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
Net Income | - | 7,244 | 5,412 | 19,404 | 8,653 | 3,422 | Upgrade
|
Depreciation & Amortization | - | 3,197 | 1,997 | 1,945 | 1,892 | 1,434 | Upgrade
|
Loss (Gain) on Equity Investments | - | 1,090 | - | - | - | - | Upgrade
|
Other Operating Activities | - | 1,982 | -8,280 | -2,520 | -801 | -1,258 | Upgrade
|
Change in Accounts Receivable | - | -3,797 | 4,448 | -7,402 | -205 | 857 | Upgrade
|
Change in Inventory | - | -2,437 | -3,877 | -1,082 | -4,699 | 258 | Upgrade
|
Change in Accounts Payable | - | 1,854 | -2,892 | 1,305 | 2,630 | 285 | Upgrade
|
Change in Other Net Operating Assets | - | 179 | -2,308 | -2,361 | 2,871 | -71 | Upgrade
|
Operating Cash Flow | - | 9,312 | -5,500 | 9,289 | 10,341 | 4,927 | Upgrade
|
Operating Cash Flow Growth | - | - | - | -10.17% | 109.88% | 26.17% | Upgrade
|
Capital Expenditures | - | -1,526 | -7,654 | -11,333 | -4,780 | -4,838 | Upgrade
|
Cash Acquisitions | - | -600 | -6,717 | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | - | -569 | -906 | - | -2,747 | - | Upgrade
|
Investment in Securities | - | - | 259 | - | 193 | 768 | Upgrade
|
Other Investing Activities | - | 5 | 16 | 8,083 | 4,044 | -91 | Upgrade
|
Investing Cash Flow | - | -2,690 | -15,002 | -3,250 | -3,290 | -4,161 | Upgrade
|
Short-Term Debt Issued | - | - | 3,000 | - | 8,320 | 1,000 | Upgrade
|
Long-Term Debt Issued | - | 9,600 | 4,750 | 750 | 1,750 | 3,050 | Upgrade
|
Total Debt Issued | - | 9,600 | 7,750 | 750 | 10,070 | 4,050 | Upgrade
|
Short-Term Debt Repaid | - | -6,900 | - | - | - | - | Upgrade
|
Long-Term Debt Repaid | - | -2,200 | -3,050 | -750 | -650 | -850 | Upgrade
|
Total Debt Repaid | - | -9,100 | -3,050 | -750 | -650 | -850 | Upgrade
|
Net Debt Issued (Repaid) | - | 500 | 4,700 | - | 9,420 | 3,200 | Upgrade
|
Repurchase of Common Stock | - | 15 | 10 | 10 | 13 | 15 | Upgrade
|
Dividends Paid | - | -2,500 | -2,739 | -2,169 | -1,083 | -989 | Upgrade
|
Other Financing Activities | - | -46 | -23 | -20 | -46 | -178 | Upgrade
|
Financing Cash Flow | - | -2,031 | 1,948 | -2,179 | 8,304 | 2,048 | Upgrade
|
Foreign Exchange Rate Adjustments | - | 886 | 1,099 | 612 | -22 | 20 | Upgrade
|
Miscellaneous Cash Flow Adjustments | - | - | 1 | - | -1 | 2 | Upgrade
|
Net Cash Flow | - | 5,477 | -17,454 | 4,472 | 15,332 | 2,836 | Upgrade
|
Free Cash Flow | - | 7,786 | -13,154 | -2,044 | 5,561 | 89 | Upgrade
|
Free Cash Flow Growth | - | - | - | - | 6148.32% | -97.04% | Upgrade
|
Free Cash Flow Margin | - | 18.16% | -38.30% | -4.00% | 18.48% | 0.36% | Upgrade
|
Free Cash Flow Per Share | - | 62.09 | -105.37 | -16.46 | 44.80 | 0.72 | Upgrade
|
Cash Interest Paid | - | 87 | 46 | 45 | 46 | 22 | Upgrade
|
Cash Income Tax Paid | - | -1,982 | 8,279 | 2,517 | 807 | 1,262 | Upgrade
|
Levered Free Cash Flow | - | 4,178 | -15,235 | 4,843 | 5,053 | 964.38 | Upgrade
|
Unlevered Free Cash Flow | - | 4,232 | -15,207 | 4,871 | 5,080 | 978.13 | Upgrade
|
Change in Net Working Capital | 6,419 | 1,578 | 11,755 | -1,800 | -5,534 | -2,354 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.